Pharmacy Board recalls paracetamol injections over safety concerns

The Pharmacy and Poisons Board (PPB) has recalled three paracetamol injections, including Lumidol, Blink, and Paragen, citing safety concerns.

PPB has ordered an immediate halt to their use, sale, distribution, and issuance, and urged the public to report any ongoing circulation of the products.

All three products- Paracetamol 100mg/100ml injections—were manufactured by KamlaAmrut Pharmaceutical LLP of India, and are said to exhibit changes in color that may indicate compromised quality.

In a statement, the PPB warned against the use of the recalled injections, citing potential health risks.

This latest recall comes amid ongoing efforts by the Board to enforce regulatory standards.

In January, PPB suspended and revoked the licenses of several pharmaceutical practitioners following investigations by its Enquiries and Disciplinary Committee, chaired by Richard Muthoka.

One of the cases involved Malibu Pharmacy, where a pharmacist was found to have authorised the delivery of medication bearing an external label that exposed a patient’s personal details and diagnosis.

In 2023, the board also recalled Tamedol, an oral paracetamol syrup used to treat pain and fever in children, after receiving multiple complaints about the quality of certain batches.